Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2018 Aug;24(8):1581-1589. doi: 10.1016/j.bbmt.2018.03.019. Epub 2018 Mar 27.

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

Author information

1
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. Electronic address: tfehnige@wustl.edu.
2
Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
3
Department of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina.
4
Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute of City of Hope, City of Hope Comprehensive Cancer Center, Duarte, California.
5
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
6
Fortress Biotech, Inc., New York, New York.
7
Department of Epidemiology and Biostatistics, SUNY Downstate School of Public Health, Brooklyn New York.
8
Department of Hematology, Royal Free Hospital, UCL Medical School, London, United Kingdom.

Abstract

Natural killer (NK) cells are an emerging immunotherapy approach to acute myeloid leukemia (AML); however, the optimal approach to activate NK cells before adoptive transfer remains unclear. Human NK cells that are primed with the CTV-1 leukemia cell line lysate CNDO-109 exhibit enhanced cytotoxicity against NK cell-resistant cell lines. To translate this finding to the clinic, CNDO-109-activated NK cells (CNDO-109-NK cells) isolated from related HLA-haploidentical donors were evaluated in a phase 1 dose-escalation trial at doses of 3 × 105 (n = 3), 1 × 106 (n = 3), and 3 × 106 (n = 6) cells/kg in patients with AML in first complete remission (CR1) at high risk for recurrence. Before CNDO-109-NK cell administration, patients were treated with lymphodepleting fludarabine/cyclophosphamide. CNDO-109-NK cells were well tolerated, and no dose-limiting toxicities were observed at the highest tested dose. The median relapse-free survival (RFS) by dose level was 105 (3 × 105), 156 (1 × 106), and 337 (3 × 106) days. Two patients remained relapse-free in post-trial follow-up, with RFS durations exceeding 42.5 months. Donor NK cell microchimerism was detected on day 7 in 10 of 12 patients, with 3 patients having evidence of donor cells on day 14 or later. This trial establishes that CNDO-109-NK cells generated from related HLA haploidentical donors, cryopreserved, and then safely administered to AML patients with transient persistence without exogenous cytokine support. Three durable complete remissions of 32.6 to 47.6+ months were observed, suggesting additional clinical investigation of CNDO-109-NK cells for patients with myeloid malignancies, alone or in combination with additional immunotherapy strategies, is warranted.

KEYWORDS:

Acute myeloid leukemia; CNDO-109–activated natural killer cells

PMID:
29597002
PMCID:
PMC6232080
[Available on 2019-08-01]
DOI:
10.1016/j.bbmt.2018.03.019

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center